Elevance Health 4Q 2023 Earnings Presentation January 24, 2024 -- 1 of 15 -- 2 Key Highlights • Elevance Health delivered another solid year of financial and operational performance, reflecting the balance and resilience of our diversified portfolio of businesses • 4Q 2023 adjusted diluted EPS of $5.62 grew 15.2% year-over-year • 2023 full year adjusted diluted EPS of $33.14 grew 16.2% year-over-year • 2018 – 2023 adjusted diluted EPS CAGR of 16% exceeded the high end of our long-term target growth rate 2023 Results 1 • 2024 adjusted diluted EPS guidance of >$37.10 reflects growth of at least 12% year-over-year • Benefit expense ratio projected to be 87.0% +/- 50 bps • Operating gain projected to be greater than $10.3B, growth of >9% year-over-year • Medical membership expected to end in the range of 45.8 – 46.6 million members 2024 Outlook 2 • Enhance the whole health of our members by serving as their lifetime, trusted health partner, especially through maximizing continuity of coverage for those subject to Medicaid redeterminations and adding key capabilities in Carelon in 2024. We will continue to live our purpose: to improve the health of humanity. • Growth in 2024 will be driven by optimizing our Health Benefits business, including through the ongoing margin recovery of our Commercial risk-based business, the strategic repositioning of our Medicare Advantage plan offerings in certain markets, continued penetration of Carelon Services capabilities in our health plans, and the transformation of our cost structure • We will continue to invest in high-growth opportunities to build upon our foundation for sustained, long- term growth • We will scale Carelon’s existing capabilities and add new ones in 2024, driving incremental earnings and accelerating our enterprise flywheel for growth Strategic Priorities 3 -- 2 of 15 -- 33 Key Highlights • Elevance Health delivered another solid year of financial and operational performance • Fourth quarter and full-year results marked by solid top and bottom-line growth • Benefit expense ratio of 87.0% for the full year represents an improvement of 60 basis points from prior year • Adjusted operating gain in 2023 grew 12.8% year-over-year to $9.4B • Results reflect the balance and resilience of our diversified portfolio of businesses, our relentless focus on customer experience and affordability, and continued investments in innovation Fourth Quarter & Full Year 2023 Results Change (%/bps/$) 2022 2023 Change (%/bps) 4Q 2022 4Q 2023 Elevance Health 9.3% $155.7B $170.2B 7.0% $39.7B $42.5B Operating Revenue 1 (60) bps 87.6% 87.0% (50) bps 89.7% 89.2% Medical Loss Ratio 0 bps 11.3% 11.3% 20 bps 11.4% 11.6% Adjusted Operating Expense Ratio1,2 12.8% $8.4B $9.4B 3.3% $1.3B $1.4B Adjusted Operating Gain1,2 (30) bps 5.3% 5.0% (20) bps 3.2% 3.0% Operating Margin 1 22.9% $1.5B $1.8B 41.8% $373M $529M Net Investment Income 16.2% $28.53 $33.14 15.2% $4.88 $5.62 Adjusted diluted EPS ($0.3B) $8.4B $8.1B ($1.5B) ($1.5B) ($3.0B) Operating Cash Flow 1. See “Basis of Presentation” on page 11 herein. 2. See “GAAP Reconciliation” on pages 12 and 13 herein. -- 3 of 15 -- 44 2023 Actual 2024 Outlook Elevance Health $142.9B Approximately Flat Premium Revenue $19.5B Mid-Single Digit Growth Product Revenue $7.9B Low Double-Digit Growth Service Fees $170.2B Flat to Low-Single Digit Growth Total Operating Revenue 87.0% 87.0% +/- 50 bps Medical Loss Ratio 11.3% 11.1% +/- 50 bps Adjusted Operating Expense Ratio $9.4B >$10.3B Adjusted Operating Gain $1.83B $1.90B Net Investment Income $33.14 >$37.10 Adjusted Diluted EPS $8.1B >$8.1B Operating Cash Flow 2024 Outlook Key Highlights • 2024 full year guidance for adjusted diluted earnings per share of greater than $37.10 reflects growth of 12% year-over-year and is consistent with our long-term compound annual growth rate target • Health Benefits 2024 outlook reflects continued optimization of our commercial risk-based business, improvement in Medicare earnings, and a reset in Medicaid membership associated with footprint changes and ongoing redeterminations • Carelon poised for strong growth in 2024 driven by new external client wins and continued expansion of services provided to Elevance Health medical members -- 4 of 15 -- 55 Key Highlights • Health Benefits delivered strong fourth quarter and full year results as we continued to optimize our business while investing for growth and responding to a dynamic environment • Commercial Health Benefits business successfully delivered margin improvement and is on track to return to pre-pandemic levels • Government Health Benefits business performed in line with expectations; we continue to execute an extensive renewal campaign to maximize continuity of coverage for consumers • 2024 earnings growth will be driven by continued optimization of the Health Benefits business including Commercial risk; strategic repositioning of Medicare Advantage; and the transformation of our cost structure Change (%/bps) 2022 2023 Change (%/bps) 4Q 2022 4Q 2023 Health Benefits 7.3% $138.5B $148.6B 4.4% $35.0B $36.5B Operating Revenue1 14.4% $6.0B $6.9B (2.3%) $785M $767M Operating Gain1 30 bps 4.3% 4.6% (10) bps 2.2% 2.1% Operating Margin 1 (1.2%) 47.5M 47.0M Membership 1. See “Basis of Presentation” on page 11 herein. 2024 Outlook Guidance Approximately flat Operating Revenue 25-50 basis points over 2023 Operating Margin 45.8M – 46.6M Membership Health Benefits 2023 Results | 2024 Outlook -- 5 of 15 -- 66 Key Highlights • Carelon continues to advance its strategy of integrating physical, behavioral, social and pharmacy services to deliver whole health, affordably • Carelon Services fourth quarter operating revenue of $3.6 billion was up 7% year-over-year and operating gain of $102 million reflects an increase of 162%, driven by improved performance as we continue to scale capabilities • External pharmacy member growth and the acquisition of the BioPlus specialty pharmacy drove CarelonRx fourth quarter operating revenue up 17% year-over-year, to $8.8 billion; operating gain was $490 million, up 3% • We continue to make significant progress toward the near-term roll-out of multiple new capabilities that will enhance affordability and consumer experiences for our customers 2023 Results | 2024 Outlook Change (%/bps) 2022 2023 Change (%/bps) 4Q 2022 4Q 2023 Carelon 15.9% $41.4B $48.0B 14.1% $10.9B $12.4B Operating Revenue 1 10.5% $2.4B $2.7B 15.2% $514M $592M Operating Gain1 (30) bps 5.8% 5.5% 10 bps 4.7% 4.8% Operating Margin 1 0.0% 308.3M 308.4M (4.9%) 82.0M 78.0M Adjusted Scripts (1.6%) 105.0M 103.3M Consumers Served 1. See “Basis of Presentation” on page 11 herein. 2024 Outlook Guidance High-Teens to Low-Twenties Carelon Services Operating Revenue Growth (30) – 0 basis points over 2023 Carelon Services Operating Margin Low-Single Digit CarelonRx Operating Revenue Growth 40 – 60 basis points over 2023 CarelonRx Operating Margin Carelon -- 6 of 15 -- 77 Flywheel Supports Sustainable, Long-Term Growth Health Benefits Optimize the Core Invest in Growth Accelerate Long-Term Adjusted Earnings Per Share Compound Annual Growth Rate Target of 12 – 15% Approximately 47M medical members balanced across commercial, Medicaid and Medicare, leveraging the assets and capabilities of Carelon to accelerate growth Integrated portfolio of whole health solutions connecting care across physical, behavioral, social, and pharmacy needs to bend the cost curve, enhance consumer experiences, and deliver whole health, affordably Carelon -- 7 of 15 -- 88 Delivered on our Targets 1. Operating Revenue and Adjusted EPS Growth long-term guidance as of March 7, 2019. % of Benefit Expense managed by Carelon guidance as of March 23, 2023. 2023 Operating Revenue and 2023 Adjusted EPS guidance as of January 25, 2023. 2. CAGR: Compound Annual Growth Rate. Status Actual Initial Guidance1 Commitment 13% CAGR (2018-2023) 10% – 12% CAGR 2 Operating Revenue Growth 16% CAGR (2018-2023) 12% – 15% CAGR Adjusted EPS Growth 21% in 2023 >20% in 2025 % of Benefit Expense Managed by Carelon $170B $164B 2023 Operating Revenue $33.14 >$32.60 2023 Adjusted Diluted EPS -- 8 of 15 -- 99 Committed to Strong Growth Over the Long-Term M&A/ Reinvest in Core 50% Share Repurchase 30% Dividends 20% 5.3% 6.5% – 7.0% 2022 2027 Target $156B Upper Single to Low Double Digit CAGR2 2022 2027 Target Elevance Health 5.8% Mid to Upper Single Digit 2022 2027 Target $41B Mid Teens CAGR2 2022 2027 Target Carelon 3 4.3% 5.5% – 6.5% 2022 2027 Target $138B Upper Single Digit CAGR2 2022 2027 Target Health Benefits Capital Allocation Long-Term Adjusted Earnings Per Share Compound Annual Growth Rate Target of 12 – 15% Operating Margin 1 Revenue1 (in Billions) 1. 2022 Operating Revenue and Operating Margin for Health Benefits, Carelon, and Elevance Health have been updated to reflect restated financials. 2. Five-Year Compound Annual Growth Rate target for 2022 – 2027. 3. The compound annual growth rate (CAGR) target for revenue from 2022 – 2027 and the operating margin target in 2027 for Carelon includes: (i) a low double-digit revenue CAGR and 6.0% – 6.5% operating margin target for CarelonRx, and (ii) an upper teens to low twenties revenue CAGR and mid to upper single-digit operating margin for Carelon Services. -- 9 of 15 -- 10 Forward-Looking Statements This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent required by law, we do not update or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof. These risks and uncertainties include, but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient premium rates; the impact of large scale medical emergencies, such as public health epidemics and pandemics, including COVID-19, and other catastrophes; the impact of new or changes in existing federal, state and international laws or regulations, including laws and regulations impacting healthcare, insurance, pharmacy services and other diversified products and services, or their enforcement or application; the impact of cyber-attacks or other privacy or data security incidents or breaches or our failure to comply with any privacy, data or security laws or regulations, including any investigations, claims or litigation related thereto; information technology disruptions; changes in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non- compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star ratings and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits or reviews; our ability to contract with providers on cost-effective and competitive terms; failure to effectively maintain and modernize our information systems; risks associated with providing healthcare, pharmacy and other diversified products and services, including medical malpractice or professional liability claims and non-compliance by any party with the pharmacy services agreement between us and CaremarkPCS Health, L.L.C.; risks associated with mergers, acquisitions, joint ventures and strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact our access to or further increase the cost of financing; a downgrade in our financial strength ratings; the effects of any negative publicity related to the health benefits industry in general or us in particular; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated with our international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations. -- 10 of 15 -- 11 Non-GAAP Measures and Basis of Presentation This document references non-GAAP measures. These non-GAAP measures are intended to aid investors when comparing Elevance Health’s financial results among periods and are not intended to be alternatives to any measure calculated in accordance with GAAP. Reconciliations of these non-GAAP measures to the most directly comparable measures calculated in accordance with GAAP are available on the last page of this document. Operating revenue and operating gain/loss are the key measures used by management to evaluate performance in each of its reporting segments, allocate resources, set incentive compensation targets and to forecast future operating performance. Operating gain/loss is calculated as total operating revenue less benefit expense, cost of products sold and operating expense. It does not include net investment income, net gains/losses on financial instruments, interest expense, amortization of other intangible assets and gains/losses on extinguishment of debt or income taxes, as these items are managed in a corporate shared service environment and are not the responsibility of operating segment management. Operating Margin is defined as operating gain divided by operating revenue. Each of these measures is provided to further aid investors in understanding and analyzing Elevance Health’s operating and financial results. -- 11 of 15 -- 12 12 Elevance Health GAAP Reconciliation — Shareholders’ Net Income and Shareholders’ Earnings Per Diluted Share Twelve Months Ended Dec 31 Three Months Ended Dec 31 Change 2022 2023 Change 2022 2023 (In millions, except per share data) (0.6)% $6,025 $5,987 (9.8)% $949 $856 Shareholders' net income - As reported (131) — (84) — Impact of Accounting Standards Update 2018-12 Adoption 1.6% $5,894 $5,987 (1.0)% $865 $856 Shareholders' net income - Restated Add / (Subtract): 550 694 111 336 Net losses on financial instruments 767 885 247 217 Amortization of other intangible assets 72 213 36 59 Transaction and integration related costs 39 719 39 22 Business optimization charges 12 6 1 1 Litigation expenses (44) (8) (20) (8) BCBSA litigation settlement (363) (628) (102) (158) Tax impact of non-GAAP adjustments 1,033 1,881 312 469 Net adjustment items 13.6% $6,927 $7,868 12.6% $1,177 $1,325 Adjusted shareholders' net income 1.7% $24.81 $25.22 (7.6)% $3.93 $3.63 Shareholders’ earnings per diluted share - As reported (0.53) — (0.34) — Impact of Accounting Standards Update 2018-12 Adoption 3.9% $24.28 $25.22 1.1% $3.59 $3.63 Shareholders’ earnings per diluted share - Restated Add / (Subtract): 2.27 2.92 0.46 1.42 Net losses on financial instruments 3.16 3.73 1.02 0.92 Amortization of other intangible assets 0.30 0.90 0.15 0.25 Transaction and integration related costs 0.16 3.03 0.16 0.09 Business optimization charges 0.05 0.03 — — Litigation expenses (0.18) (0.03) (0.08) (0.03) BCBSA litigation settlement (1.50) (2.65) (0.42) (0.67) Tax impact of non-GAAP adjustments 4.25 7.92 1.29 1.99 Net adjustment items 16.2% $28.53 $33.14 15.2% $4.88 $5.62 Adjusted shareholders’ earnings per diluted share -- 12 of 15 -- 13 13 Elevance Health GAAP Reconciliation — Operating Expense Ratio and Operating Gain Twelve Months Ended Dec 31 Three Months Ended Dec 31 Change 2022 2023 Change 2022 2023 (In millions) 13.6% $17,686 $20,087 9.6% $4,562 $4,999 Operating expense - As reported 14 — 5 — Impact of Accounting Standards Update 2018-12 Adoption 13.5% $17,700 $20,087 9.5% $4,567 $4,999 Operating expense - Restated Add / (Subtract): (72) (213) (36) (59) Transaction and integration related costs (39) (719) (39) (22) Business optimization charges (12) (6) (1) (1) Litigation expenses 44 8 20 8 BCBSA litigation settlement (79) (930) (56) (74) Net adjustment items 8.7% $17,621 $19,157 9.2% $4,511 $4,925 Adjusted operating expense 1.5% $7,600 $7,715 (4.2)% $1,045 $1,001 Income before income tax expense (1,485) (1,825) (373) (529) Net investment income 550 694 111 336 Net losses on financial instruments 851 1,030 229 259 Interest expense 767 885 247 217 Amortization of other intangible assets 2.6% $8,283 $8,499 2.0% $1,259 $1,284 Reportable segments operating gain 79 930 56 74 Adjustment items 12.8% $8,362 $9,429 3.3% $1,315 $1,358 Reportable segments adjusted operating gain 9.3% $155,660 $170,209 7.0% $39,667 $42,454 Operating revenue 40 bp 11.4% 11.8% 30 bp 11.5% 11.8% Operating expense ratio — bp 11.3% 11.3% 20 bp 11.4% 11.6% Adjusted operating expense ratio -- 13 of 15 -- 14 14 Elevance Health GAAP Reconciliation — 2024 Outlook Full Year 2024 Outlook Greater than $34.29 Shareholders’ earnings per diluted share Add / (Subtract): $1.93 Amortization of other intangibles $1.35 Net losses on financial instruments $0.31 Transaction and integration related costs $0.03 Litigation expenses Approximately $(0.81) Tax impact of non-GAAP adjustments $2.81 Net adjustment items Greater than $37.10 Adjusted shareholders’ earnings per diluted share -- 14 of 15 -- -- 15 of 15 --